High Prevalence of Myocardial Ischemia and Vasoconstrictive Hormonal Release in Hypertension during Chronic Renal Failure

Nephron ◽  
1997 ◽  
Vol 76 (4) ◽  
pp. 434-444 ◽  
Author(s):  
Claudio Napoli ◽  
Fernando Di Gregorio ◽  
Pompeo Sorice ◽  
Attilio Di Benedetto ◽  
Silvia Ciafre ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Myocardial Ischemia ◽  
High Prevalence ◽  
Hormonal Release

High Prevalence of Hypogonadism in Male Patients with Chronic Renal Failure

2011 ◽  
pp. P3-215-P3-215
Author(s):  
Walter Reinhardt ◽  
Vasili Bouronikou ◽  
Sebastian Dolff ◽  
Martina Broecker ◽  
Klaus Mann ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
High Prevalence ◽  
Male Patients

Aluminum-associated bone disease in chronic renal failure: High prevalence in a long-term dialysis population

2009 ◽  
Vol 1 (5) ◽  
pp. 391-398 ◽  
Author(s):  
Dennis L. Andress ◽  
Norma A. Maloney ◽  
David B. Endres ◽  
Donald J. Sherrard
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Bone Disease ◽  
High Prevalence

scholarly journals Medical and Periodontal Clinical Parameters in Patients at Different Levels of Chronic Renal Failure

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Caroline Perozini ◽  
Gilson Fernandes Ruivo ◽  
Lucilene Hernandes Ricardo ◽  
Larissa Avance Pavesi ◽  
Yeon Jung Kim ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Multidisciplinary Approach ◽  
Early Stage ◽  
Renal Involvement ◽  
Clinical Attachment Loss ◽  
Periodontal Tissues ◽  
High Prevalence ◽  
Systemic Health ◽  
Different Levels

Aim. To assess the clinical periodontal and medical parameters in patients with chronic renal failure (CRF) at different levels of renal disease.Background. CRF is a progressive and irreversible loss of renal function associated with a decline in the glomerular filtration rate. Periodontal disease is a destructive inflammatory disease affecting periodontal tissues that shows high prevalence in patients with CRF.Materials and Methods. 102 CRF patients were included and divided into an early stage group (EG), predialysis group (PDG), and hemodialysis group (HDG). The medical parameters were taken from the patients’ records.Results. Periodontal clinical condition differed among the CRF groups. Clinical attachment loss was greater in the HDG and PDG group compared to the EG (p=0.0364); the same was observed in the Plaque Index (p=0.0296); the others periodontal parameters did not show any differences. Ferritin levels were significantly higher in the HDG when compared to the EG and PGD (p<0.0001), and fibrinogen was higher in PDG compared with the others (p<0.0001); the triglycerides also showed higher values in the HDG compared with the other groups (p<0.0001).Conclusion. The patients with renal involvement should have a multidisciplinary approach to an improvement in their oral and systemic health.

scholarly journals Comparison of the effects of pramipexole and gabapentin on the treatment of restless leg syndrome in end-stage chronic renal failure patients undergoing hemodialysis

2020 ◽  
Vol 9 (3) ◽  
pp. e25-e25
Author(s):  
Sepideh Hajian ◽  
Mohammad Reza Rajabpoor Nikfam ◽  
Zahra Esmayeilzad
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Diagnostic Criteria ◽  
Restless Legs Syndrome ◽  
Hemodialysis Patients ◽  
Restless Leg Syndrome ◽  
Restless Legs ◽  
High Prevalence ◽  
End Stage ◽  
Rate Of Improvement

Introduction: Despite the high prevalence of restless legs syndrome (RLS) in hemodialysis patients, few studies have investigated the effect of pramipexole and gabapentin on the severity of RLS in these patients. Objectives: The study aimed to evaluate the effects of pramipexole and gabapentin on the treatment of RLS in end-stage chronic renal failure patients undergoing hemodialysis. Patients and Methods: Using the diagnostic criteria the presence of RLS was investigated in all hemodialysis patients admitted to the dialysis ward of Bu Ali Sina and Velayat hospitals in Qazvin, Iran. Out of 162 patients, 96 patients had RLS and 60 patients with moderate to severe RLS were enrolled in the study. The selected patients were randomly divided into two groups including pramipexole (0.18 mg daily) and gabapentin (100 mg daily). The two groups were treated for 4 weeks. Results: The prevalence of RLS was 59% (96 out of 162 patients). After the intervention, the severity of RLS was significantly decreased in all patients and also in each of the pramipexole and gabapentin groups (P<0.001). Moreover, after the intervention, the rate of improvement in RLS severity in the pramipexole group (16.8 ± 6.5) was significantly higher than that in the gabapentin group (13.0 ± 7.3; P=0.036). Conclusion: The findings of the study showed that the severity of RLS in hemodialysis patients undergoing 4 weeks of treatment with pramipexole or gabapentin was significantly reduced; in addition, the rate of improvement in RLS severity was higher in pramipexole group.

Sign in / Sign up

Export Citation Format

Share Document